Focused On-demand Library for Cleavage and polyadenylation specificity factor subunit 3

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q9UKF6

UPID:
CPSF3_HUMAN

ALTERNATIVE NAMES:
Cleavage and polyadenylation specificity factor 73 kDa subunit; mRNA 3'-end-processing endonuclease CPSF-73

ALTERNATIVE UPACC:
Q9UKF6; O14769; Q53RS2; Q96F36

BACKGROUND:
The mRNA 3'-end-processing endonuclease CPSF-73, a component of the cleavage and polyadenylation specificity factor complex, is integral to histone pre-mRNA processing and microRNA biogenesis. Its ability to bind and process RNA substrates is essential for S-phase progression in the cell cycle, showcasing its critical function in cellular replication and gene expression regulation.

THERAPEUTIC SIGNIFICANCE:
Given its association with a severe neurodevelopmental disorder, exploring CPSF-73's function offers a promising avenue for developing targeted treatments. The protein's genetic link to disease underscores the potential for innovative therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8430 of 8789